ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACOR - iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Jan 11, 2018 3:30 PM ET

ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACOR

Legal Newswire iCrowdNewswire - Jan 11, 2018

NEW YORK,  — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acorda Therapeutics, Inc. (NASDAQ:ACOR) from April 18, 2016 through November 14, 2017, inclusive (the “Class Period”) of the important January 17, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Acorda investors under the federal securities laws.

To join the Acorda class action, go to http://rosenlegal.com/cases-1242.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) tozadenant entailed significant undisclosed safety risks; (2) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (3) for the foregoing reasons, the Company had likewise overstated the benefits of the Biotie Acquisition; and (4) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1242.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Daniel Sadeh, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

View Related News >